In this roundup, experts outline diverging pediatric COVID vaccine recommendations, midlife peaks in long COVID risk, new findings on abnormal uterine bleeding and cycle-related symptoms in long COVID, and...
New multicenter US data show that a single respiratory syncytial virus (RSV) vaccine dose protects against hospitalization in older adults, though effectiveness wanes over time and is lower in...
In a phase 1 trial, a single injection of an mRNA RSV vaccine boosted neutralizing antibody levels in seropositive children and was well tolerated, with no serious adverse events or study discontinuations...
This respiratory disease roundup covers the potential impact of a new COVID-19 variant, changes in funding for pandemic influenza vaccines, and a study on cardiac event risks in respiratory syncytial virus...
Emerging research explores how a wearable device may identify infection before symptoms appear, which treatments reduce hospitalizations, and who remains most at risk.
From respiratory syncytial virus monoclonal antibody approvals to thimerosal-free vaccine preferences, ACIP’s latest guidance has important implications for your practice.
Recent studies show distinct metabolic disruptions in children with multisystem inflammatory syndrome in children, plaque progression in adults post–COVID-19, and surprising pneumococcal risk patterns.
...
New research explores long COVID risks in children, ACIP's expanded RSV vaccine use, U.S. disease resurgence under falling immunization, and long COVID’s burden on health care workers.
In this respiratory disease roundup, researchers report on the efficacy of nirmatrelvir-ritonavir for treating Long COVID, the CDC updates recommendations on “triple threat” vaccines for respiratory virus...
